Bajaj Healthcare enters highly regulated opiate processing business

The Indian opiate market holds good potential and the receipt of this order opens the doors to a new business vertical with better margins, he added.

Published On 2022-07-13 10:57 GMT   |   Update On 2022-07-13 10:57 GMT

Gujarat: Bajaj Healthcare on Wednesday said it has forayed into the highly regulated opiate processing business.

The company said it has received two orders from the central government to produce active pharmaceutical ingredients from poppy capsules and other derivatives on an annual basis.
It plans to execute both these tenders from its API manufacturing unit located at Savli, Gujarat.
"We have been awarded two tenders for the supply of Opium derived Alkaloids and APIs to the GOI, under long-term contracts and expect successive orders under similar tenders to scale up to the processing of 6,000 MT of Poppy Straw and Opium Gum in the next five years," Bajaj Healthcare Joint Managing Director Anil Jain said in a regulatory filing.
Advertisement
The Indian opiate market holds good potential and the receipt of this order opens the doors to a new business vertical with better margins, he added.
"This is for the first time in the history of the nation that the government has deregulated Opiate Processing to a private player, and we are extremely honoured to be awarded the very first tender in this segment," Jain said.

Bajaj Healthcare Limited a manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation.

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News